长春高新：子公司GenSci142胶囊注册临床试验申请获批

Core Viewpoint - Changchun High-tech announced that its subsidiary, Gensci Pharmaceutical, received approval from the National Medical Products Administration for the clinical trial application of GenSci142 capsules, an innovative biological product aimed at treating bacterial vaginosis. This approval marks the first clinical trial application granted under the "30-day channel" for innovative drug review and approval since its introduction [1]. Group 1 - Gensci Pharmaceutical's GenSci142 capsules are classified as a Class 1 innovative biological product [1]. - The approval is significant as it represents a milestone in the expedited review process for innovative drugs in China [1]. - The product is specifically intended for the treatment of bacterial vaginosis, indicating a targeted therapeutic approach [1].